INVAGESIC FORTE

Clinical safety rating: caution

Comprehensive clinical and safety monograph for INVAGESIC FORTE (INVAGESIC FORTE).

How it works

Combination of an opioid agonist (codeine) and a non-opioid analgesic (ibuprofen). Codeine is metabolized to morphine, which binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Ibuprofen inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby decreasing inflammation and pain.

What the body does with it

Metabolism	Codeine is metabolized via CYP2D6 to morphine, and via CYP3A4 to norcodeine. Ibuprofen is metabolized primarily via CYP2C9.
Excretion	Renal: 90% (70% unchanged, 20% as glucuronide conjugate); Fecal/biliary: <5%
Half-life	Terminal half-life: 2-3 hours (prolonged in renal impairment; clinical context: requires dosing interval adjustment in CrCl <30 mL/min)
Protein binding	99% (primarily albumin; binding reduced in hypoalbuminemia, uremia, and neonates)
Volume of Distribution	0.1-0.2 L/kg (clinical meaning: low Vd indicates limited extravascular distribution, consistent with high protein binding and acidic drug nature)
Bioavailability	Oral: 80-100% (food delays absorption but does not reduce extent)
Onset of Action	Oral: 30-60 minutes; Intramuscular: 10-20 minutes; Intravenous: 1-2 minutes
Duration of Action	Oral: 4-6 hours; Intramuscular/Intravenous: 2-4 hours (clinical notes: analgesic effect wanes before anti-inflammatory effect due to central vs peripheral COX inhibition)

Classification & Brands

Dosing & administration

One tablet (hydrocodone bitartrate 10 mg / acetaminophen 300 mg / ibuprofen 200 mg) orally every 4 to 6 hours as needed for pain; maximum 5 tablets per day.

Dosage form	TABLET
Renal impairment	Contraindicated in severe renal impairment (eGFR < 30 mL/min/1.73 m²). For moderate impairment (eGFR 30-59 mL/min/1.73 m²): use lowest effective dose, maximum 4 tablets per day; avoid in dialysis.
Liver impairment	Contraindicated in Child-Pugh class C (severe hepatic impairment). For class B (moderate): reduce dose by 50% and monitor; do not exceed 4 tablets per day. Class A (mild): no adjustment but caution.
Pediatric use	Not recommended for pediatric patients under 18 years of age due to risk of serious adverse effects.
Geriatric use	Start at lower end of dosing range (e.g., 1 tablet every 6 hours); maximum 4 tablets per day. Avoid in patients with creatinine clearance < 30 mL/min. Monitor for renal function, hepatic function, and gastrointestinal bleeding.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for INVAGESIC FORTE (INVAGESIC FORTE).

Breastfeeding	Diclofenac excreted in breast milk in low amounts (M/P ratio ~0.02-0.05); paracetamol M/P ratio ~1.0. Both considered compatible with breastfeeding at recommended doses. However, avoid if infant has hypersensitivity or G6PD deficiency. Monitor infant for sedation or respiratory depression if used with opioids.
Teratogenic Risk	Pregnancy Category D for NSAID component (diclofenac): Avoid in third trimester due to risk of premature ductus arteriosus closure and oligohydramnios. First and second trimester use associated with increased risk of miscarriage and cardiac malformations. Paracetamol component is generally considered low risk but chronic high doses may increase risk of fetal hepatotoxicity.

Warnings & precautions

■ FDA Black Box Warning

Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion (especially in children); neonatal opioid withdrawal syndrome; risk from concomitant use with benzodiazepines or other CNS depressants; cytochrome P450 2D6 ultra-rapid metabolizers (risk of life-threatening respiratory depression from codeine).

Side Effect Profile

Serious Effects

Absolute Contraindications

Hypersensitivity to codeine, ibuprofen, or any component; patients with significant respiratory depression; acute or severe bronchial asthma (in an unmonitored setting or without resuscitative equipment); gastrointestinal bleeding; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; in the setting of coronary artery bypass graft (CABG) surgery; children <12 years old; breastfeeding (ultra-rapid metabolizers of codeine).

Clinical Precautions

Precautions

Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; ultra-rapid metabolism of codeine (CYP2D6); gastrointestinal bleeding (NSAIDs); cardiovascular thrombotic events; renal toxicity; hepatic impairment; elderly patients; pregnancy.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

INVAGESIC FORTE

Clinical safety rating: caution

Comprehensive clinical and safety monograph for INVAGESIC FORTE (INVAGESIC FORTE).

How it works

What the body does with it

Metabolism	Codeine is metabolized via CYP2D6 to morphine, and via CYP3A4 to norcodeine. Ibuprofen is metabolized primarily via CYP2C9.
Excretion	Renal: 90% (70% unchanged, 20% as glucuronide conjugate); Fecal/biliary: <5%
Half-life	Terminal half-life: 2-3 hours (prolonged in renal impairment; clinical context: requires dosing interval adjustment in CrCl <30 mL/min)
Protein binding	99% (primarily albumin; binding reduced in hypoalbuminemia, uremia, and neonates)
Volume of Distribution	0.1-0.2 L/kg (clinical meaning: low Vd indicates limited extravascular distribution, consistent with high protein binding and acidic drug nature)
Bioavailability	Oral: 80-100% (food delays absorption but does not reduce extent)
Onset of Action	Oral: 30-60 minutes; Intramuscular: 10-20 minutes; Intravenous: 1-2 minutes
Duration of Action	Oral: 4-6 hours; Intramuscular/Intravenous: 2-4 hours (clinical notes: analgesic effect wanes before anti-inflammatory effect due to central vs peripheral COX inhibition)

Classification & Brands

Dosing & administration

One tablet (hydrocodone bitartrate 10 mg / acetaminophen 300 mg / ibuprofen 200 mg) orally every 4 to 6 hours as needed for pain; maximum 5 tablets per day.

Dosage form	TABLET
Renal impairment	Contraindicated in severe renal impairment (eGFR < 30 mL/min/1.73 m²). For moderate impairment (eGFR 30-59 mL/min/1.73 m²): use lowest effective dose, maximum 4 tablets per day; avoid in dialysis.
Liver impairment	Contraindicated in Child-Pugh class C (severe hepatic impairment). For class B (moderate): reduce dose by 50% and monitor; do not exceed 4 tablets per day. Class A (mild): no adjustment but caution.
Pediatric use	Not recommended for pediatric patients under 18 years of age due to risk of serious adverse effects.
Geriatric use	Start at lower end of dosing range (e.g., 1 tablet every 6 hours); maximum 4 tablets per day. Avoid in patients with creatinine clearance < 30 mL/min. Monitor for renal function, hepatic function, and gastrointestinal bleeding.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for INVAGESIC FORTE (INVAGESIC FORTE).

Breastfeeding	Diclofenac excreted in breast milk in low amounts (M/P ratio ~0.02-0.05); paracetamol M/P ratio ~1.0. Both considered compatible with breastfeeding at recommended doses. However, avoid if infant has hypersensitivity or G6PD deficiency. Monitor infant for sedation or respiratory depression if used with opioids.
Teratogenic Risk	Pregnancy Category D for NSAID component (diclofenac): Avoid in third trimester due to risk of premature ductus arteriosus closure and oligohydramnios. First and second trimester use associated with increased risk of miscarriage and cardiac malformations. Paracetamol component is generally considered low risk but chronic high doses may increase risk of fetal hepatotoxicity.